Halozyme Therapeutics (HALO) Tops Q3 EPS by 4c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $74.96 --0%
EPS Growth %: +17.5%
Financial Fact:
Product sales: 13.33M
Today's EPS Names:
DTGI, OCCI, MAYS, More
EPS Growth %: +17.5%
Financial Fact:
Product sales: 13.33M
Today's EPS Names:
DTGI, OCCI, MAYS, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q3 EPS of ($0.19), $0.04 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $25.6 million versus the consensus estimate of $30.42 million.
GUIDANCE:
Halozyme Therapeutics sees FY2018 revenue of $150-160 million, versus the consensus of $127.8 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- New leader board: Citi refreshes AI compute semiconductor picks
- Aqua Capital lifts Energizer (ENR) stake to 7.34M shares as stock trades at 7.9x P/E
- BlackBerry (BB) Tops Q1 EPS by 1c, Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
